News | June 07, 2022
NewAmsterdam Pharma shares new data from Phase 2b ROSE Study
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India
Report lays out blueprint for achieving Organon’s purpose and business imperatives to help women and girls achieve their promise through better health
Besides enhancing workflow operations by connecting scientists with their lab instruments and data, digitalization holds the potential to acceleratee long-term business growth
By 2025, Cipla plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry.
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
The centre works with active pharmaceutical ingredients (APIs) and can utilize innovative concepts with model APIs
Each member of Fitelo's team of experts gives highly personalized attention and recommendations to their clients ensuring they reach their fitness goals holis
Approval follows CHMP recommendation for use in patients previously vaccinated with Vaxzevria or an EU-approved mRNA Covid-19 vaccine
Subscribe To Our Newsletter & Stay Updated
